TNSN05019A1 - DOSAGE FORM OF PRAMIPEXOLE ADMINISTRATION ONCE A DAY - Google Patents

DOSAGE FORM OF PRAMIPEXOLE ADMINISTRATION ONCE A DAY

Info

Publication number
TNSN05019A1
TNSN05019A1 TNP2005000019A TNSN05019A TNSN05019A1 TN SN05019 A1 TNSN05019 A1 TN SN05019A1 TN P2005000019 A TNP2005000019 A TN P2005000019A TN SN05019 A TNSN05019 A TN SN05019A TN SN05019 A1 TNSN05019 A1 TN SN05019A1
Authority
TN
Tunisia
Prior art keywords
pramipexole
composition
hours
average
day
Prior art date
Application number
TNP2005000019A
Other languages
French (fr)
Inventor
Ernest J Lee
Gerard M Bredael
John R Baldwin
Steven R Cox
Mark J Heintz
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/023522 external-priority patent/WO2004010999A1/en
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN05019A1 publication Critical patent/TNSN05019A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique pouvant être administrée par voie orale comprend une quantité thérapeutiquement efficace de pramipexole ou d'un de ses sels pharmaceutiquement acceptable, et au moins un excipient pharmaceutiquement acceptable, ladite composition présentant au moins un ou des profils consistant en (a) un profil de libération in vitro dans lequel, en moyenne, une proposition non supérieure à environ 20 % du pramipexole est dissoute dans les 2 heures suivant la mise en place de la composition dans un essai de dissolution classique ; (b) un profil d'absorption de pramipexole in vivo après administration d'une dose unique à des êtres humains adultes sains, dans lequel le temps pour atteindre une moyenne de 20 % d'absorption est supérieur à environ 2 heures et/ou le temps pour atteindre une moyenne d'environ 40 % d'absorption est supérieur à 4 heures. La composition est utile pour l'administration orale, pas plus d'une fois par jour, à un sujet présentant une affection ou un trouble pour lequel un agoniste du récepteur de dopamine est indiqué.The present invention relates to an orally administrable pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, said composition having at least one or more profiles consisting of a) an in vitro release profile in which, on average, a proposal no greater than about 20% of the pramipexole is dissolved within 2 hours of placement of the composition in a conventional dissolution test; (b) a pramipexole uptake profile in vivo after single dose administration to healthy adult humans, wherein the time to reach an average of 20% absorption is greater than about 2 hours and / or the time to reach an average of about 40% absorption is greater than 4 hours. The composition is useful for oral administration, no more than once a day, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.

TNP2005000019A 2002-07-25 2005-01-25 DOSAGE FORM OF PRAMIPEXOLE ADMINISTRATION ONCE A DAY TNSN05019A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
PCT/US2003/023522 WO2004010999A1 (en) 2002-07-25 2003-07-25 Pramipexole once-daily dosage form

Publications (1)

Publication Number Publication Date
TNSN05019A1 true TNSN05019A1 (en) 2007-05-14

Family

ID=38181237

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2005000020A TNSN05020A1 (en) 2002-07-25 2005-01-25 PRAMIPEXOLE COMPOSITION NOT CONSISTING OF PROLONGED RELEASE PRAMIPEXOLE COMPOSITION
TNP2005000019A TNSN05019A1 (en) 2002-07-25 2005-01-25 DOSAGE FORM OF PRAMIPEXOLE ADMINISTRATION ONCE A DAY

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TNP2005000020A TNSN05020A1 (en) 2002-07-25 2005-01-25 PRAMIPEXOLE COMPOSITION NOT CONSISTING OF PROLONGED RELEASE PRAMIPEXOLE COMPOSITION

Country Status (2)

Country Link
CR (1) CR7660A (en)
TN (2) TNSN05020A1 (en)

Also Published As

Publication number Publication date
CR7660A (en) 2005-06-08
TNSN05020A1 (en) 2007-05-14

Similar Documents

Publication Publication Date Title
RS115104A (en) Pramipexole once-daily dosage form
MA30335B1 (en) MODIFIED RELEASE ANTIBIOTIC COMPOSITIONS AND PROCESS FOR THEIR PRODUCTION
AR040681A1 (en) COMPOSITION OF PRAMIPEXOL SUSTAINED RELEASE TABLETS
FI3067043T3 (en) Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
RU2005115855A (en) COMPOSITION OF TRAMADOL PROLONGED BY RELEASE WITH 24 HOUR ACTION
MA29744B1 (en) SOLID DOSAGE FORMULATIONS OF MEDICAMENTS HAVING IMPROVED ORAL ADSORPTION
Bagheri et al. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs
RS20050470A (en) Solid drug for oral use
MA31397B1 (en) Salts (4 -) - (6-fluoro-7-melamine-2,4-diphenoxo-4.1-diphenylhydro-h2-quinazolin-3yl) -5-chloro-thiophene-2yl-sulfonylurea Shapes and processes to which they are associated.
US20080076820A1 (en) Method for treating neurodegeneration
US20080027052A1 (en) Methods for treating cystic kidney disease
RU2003109606A (en) PHARMACEUTICAL COMPOSITIONS
EP0530311A1 (en) The use of phenylpropanolamine as a mucus secretagogue in the upper airways
TNSN05019A1 (en) DOSAGE FORM OF PRAMIPEXOLE ADMINISTRATION ONCE A DAY
JP2005533069A (en) Combination therapy using serotonin reuptake inhibitors
KR100889086B1 (en) Method of Treatment
FR2792199A1 (en) USE OF OSANETANT FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OF MOOD DISORDERS
TW383337B (en) Process of making (2S,5S)-5-fluoromethylornithine
KR20010110798A (en) Method for treating neurodegeneration
PT95698B (en) Process for the preparation of pharmaceutical compositions containing arylalkylamines used in the treatment of neurological diseases
DZ3273A1 (en) NEW ORAL GALENIC FORM WITH EXTENDED RELEASE OF MOLSIDOMINE
WO2019009359A1 (en) Pharmaceutical composition for nasal administration
CA1027866A (en) Vincamin and theophyllin based drug and therapeutic use thereof
KR930004646B1 (en) Pharmaceutical composition for prophylaxis and treatment of cardiac hypertrophy
WO2004028456A2 (en) Method and composition for treating neurodegenerative disorders